RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA®) therapeutic platform. The Company’s discovery and research efforts are focused on […]
Multikine® Therapy Treats Newly Diagnosed Head and Neck Cancer Patients Before They Undergo Surgery, Radiation, or Chemotherapy CEL-SCI Corporation is a publicly-traded (NYSE: CVM) Phase III cancer immunotherapy company with operations in […]
Aphios Pharma is Now Developing Cannabis-Based Treatment for Opioid Addition Aphios Corporation is a Woburn, MA-based, clinical-stage biotechnology company that is developing green enabling technology platforms to improve drug discovery, manufacturing, nanotechnology […]
Therapy Targets AFP Receptors Found in Over 80 Percent of Cancer Cells Alpha Cancer Technologies Inc. (ACT) is a Toronto-based clinical-stage biotechnology company that is developing drugs for oncology and auto-immune disease […]
RNA Disruption Assay™ Test Can Determine Degree of Ribosomal RNA Disruption During Chemotherapy Rna Diagnostics Inc. is a Toronto-based early-stage molecular diagnostics company that is developing medical diagnostic tools to assist in […]
“20/20 Hindsight” Platform Improves Accuracy of Most Widely Used Cancer Biomarkers 20/20 GeneSystems, Inc. is a Rockville, MD-based, digital diagnostics company focused on reducing cancer mortality through early detection. 20/20 GeneSystems is […]
Q1© Platform Takes Unique Approach to Isolation and Interrogation of Individual Cancer Cells QuantumCyte is a Silicon Valley-based early-stage biotechnology company that is developing a unique drug assay system. QuantumCyte’s single-cell analysis […]
CAR T Cell Therapy May Change Cancer Patients’ Own Weak T Cells into “Bionic Killing Machines” Aurora Biopharma is a Cambridge, MA-based, clinical-stage company that is developing state-of-the-art cancer immunotherapy, utilizing a […]
